7.7x
asthma death rate, Black vs. white children (CDC, 2021 NHIS)
Overview
In 2021 the asthma death rate among non-Hispanic Black children was 7.7 per million, compared with 1.0 per million among non-Hispanic white children, a 7.7-fold gap (Pate and Zahran, Preventing Chronic Disease, 2024, PMID 39024520). That same year, current asthma prevalence was 12.5 percent in Black children versus 5.7 percent in white children, and Black adults sat at 10.7 percent versus 8.0 percent in white adults (CDC NHIS, 2021). Asthma is a chronic disease of the airways in which the bronchial tubes narrow, swell, and produce extra mucus in response to triggers; the diagnosis is established by spirometry showing reversible airflow obstruction, not by a peak-flow reading alone.
What sits underneath the diagnosis for most Black patients is not a single broken gene or a personality flaw about adherence. It is a stack of housing, air, insurance, and pharmacology decisions made by other people, often decades before the patient was born.
How Asthma affects Black patients
The clinical numbers are not subtle. Using 2020 healthcare-utilization data, Black children had 89.5 emergency department visits per 10,000 for asthma, compared with 14.4 per 10,000 among white children, roughly a 6-fold difference, and 8.6 inpatient stays per 10,000 versus 1.5 (Pate and Zahran, 2024). Black adults had 80.6 ED visits per 10,000 versus 27.8 for the total population, and asthma mortality of 29.7 per million versus 13.1 overall.
Three drivers account for most of that gap, and none are genetic in the lay sense.
First, where people live. The 2022 Pittsburgh registry study by Schuyler and Wenzel (American Journal of Respiratory and Critical Care Medicine, 2022, PMID 35612914) linked 1,034 asthma patients to historical Home Owners' Loan Corporation maps from the 1930s. Neighborhoods graded D, the redlined zones that were disproportionately Black, showed elevated PM2.5, sulfur dioxide, carbon monoxide, and VOC emissions almost a century later. Black participants living in grade-D tracts carried a relative risk of 2.30 for uncontrolled or severe asthma compared with Black participants in higher-graded tracts. The mechanism is concrete: diesel highway corridors, industrial sites, port traffic, and older housing stock with mold and cockroach allergens cluster inside lines that federal appraisers drew on purpose.
Second, bronchodilator response is not uniform across ancestry. Burchard's lab at UCSF, working with the SAGE II cohort of 949 African American children with asthma and replicating in 1,325 African American adults from SAPPHIRE, found a chromosome-9 variant (rs73650726) common in African-ancestry populations and rare elsewhere that is associated with reduced response to short-acting beta-agonists (Mak et al., Pharmacogenomics Journal, 2018, PMID 30206298). The clinical translation: a Black child whose albuterol seems to stop working during an exacerbation may not be exaggerating or using the inhaler wrong. The drug-response curve was built on populations that did not include them.
Third, the SABA-overuse pattern. The SABINA cohort (Nwaru et al., European Respiratory Journal, 2020, PMID 31949111) showed that filling three or more short-acting beta-agonist canisters per year was associated with dose-dependent increases in exacerbations and all-cause mortality, and that 28 percent of overusers were collecting no anti-inflammatory medication at all. In the United States, Black patients are the population most likely to be on a SABA-only regimen with an under-prescribed or unfilled inhaled corticosteroid. If your reliever is still albuterol alone in 2026, the guideline has changed; ask why your prescription has not.
Symptoms
- Wheeze, especially on exhalation, that wakes you at night or comes on after exercise, cold air, or upper respiratory infections
- Chest tightness that some patients describe as a band, a weight, or sitting on the chest
- Cough that lingers for weeks after a cold, or a dry cough that is worse at night or early morning
- Shortness of breath that is out of proportion to the activity (climbing one flight, walking to the bus stop)
- A reliever inhaler you reach for more than twice a week, or one canister lasting less than a month
- In children: recurrent bronchitis, fatigue at recess, missed school days clustered in the fall and spring
When to see a doctor
Same-week visit if you are using a rescue inhaler more than twice a week, waking from sleep coughing or wheezing more than twice a month, or limiting activity because of breathing. Urgent or emergency care if your reliever is not opening you up within 20 minutes, you cannot speak in full sentences, your lips or fingertips look gray or bluish, peak flow is below 50 percent of your personal best, or a child is sucking in between the ribs or above the collarbone with each breath. Black adults and children are disproportionately diagnosed in the ED rather than primary care; do not wait for a crisis to establish a controller plan.
Screening
There is no population screening test for asthma. Diagnosis rests on a compatible history plus objective evidence of variable airflow obstruction. The NHLBI 2020 Focused Updates and the 2007 EPR-3 guidelines both recommend spirometry, pre- and post-bronchodilator, as the diagnostic standard. An FEV1 that rises by 12 percent or more (and at least 200 mL in adults) after albuterol confirms reversibility. Peak flow meters are monitoring tools, not diagnostic ones; reference values vary too widely between devices to be used in isolation for diagnosis, but a peak-flow diary kept over two to four weeks is useful for tracking control. For children under five, diagnosis is clinical: pattern of symptoms, response to a treatment trial, and exclusion of alternatives. Fractional exhaled nitric oxide (FeNO) and methacholine challenge are second-line tests when spirometry is normal but symptoms are convincing.
Treatment overview
The 2024 GINA Strategy Report restructured adult and adolescent treatment around a preferred Track 1: low-dose inhaled corticosteroid combined with formoterol, used both as the daily controller and as the as-needed reliever, anti-inflammatory reliever (AIR) therapy. Across the pooled trial data, low-dose ICS-formoterol reduces severe exacerbations by half to two-thirds compared with SABA alone. SABA-only treatment is no longer recommended for any adult or adolescent with asthma at any severity, including mild disease.
The NHLBI 2020 Focused Updates align with this direction for the U.S., endorsing single maintenance and reliever therapy (SMART) with ICS-formoterol for patients aged four and up with moderate-to-severe disease. Biologic add-ons (omalizumab for IgE-driven disease, mepolizumab/benralizumab/dupilumab for eosinophilic phenotypes, tezepelumab for broader Type 2 and low-T2 disease) are step-5 options when high-dose ICS-LABA plus add-ons fail to control symptoms; eligibility hinges on biomarkers (IgE, blood eosinophils, FeNO) that should be checked before assuming a patient has treatment-resistant asthma. For Black patients specifically, two practical asks: confirm the prescription is ICS-containing and not SABA-only, and confirm the inhaler technique with a pharmacist, because spacer use and inspiratory flow drive whether the drug reaches the small airways at all.
Questions to ask your doctor
Bring this list to your next appointment.
- Is my reliever an ICS-formoterol combination, or am I still on albuterol alone? If albuterol alone, why?
- Can we run spirometry to confirm the diagnosis and document my baseline FEV1?
- How many rescue-inhaler canisters have I filled in the last twelve months? Is that overuse?
- Have I had blood eosinophils, total IgE, or FeNO checked? Would a biologic apply to me?
- What is my written asthma action plan, and what peak-flow number means yellow zone versus red zone for me?
- Are there mold, pest, or air-quality exposures at home or school we should address, and can you refer me to a community health worker or Medicaid home-remediation program?
- If my albuterol does not feel like it opens me up the way it should, is that something to investigate rather than ignore?
Find a Pulmonology
Search our directory of verified Black health providers who specialize in pulmonology.
Browse Pulmonology providersMedical disclaimer
This content is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. If you are experiencing a medical emergency, call 911 or your local emergency number immediately.